Cancer/Tumor Profiling Market Projected to have a Stable Growth for the Upcoming Years

by Vijay K. Web Marketing
The cancer/tumor profiling market size is projected to reach $87.1 billion by 2023. The market is growing mainly due to the increasing number of new cancer cases, rising utility of biomarkers in tumor profiling, rising availability of funding for cancer research and increasing demand for next generation sequencing for cancer profiling.

The players in the market are developing different biomarkers based on what is to be detected in a patient. For instance, Caris Life Sciences, develops several biomarkers that are based on IHC, that detects the level of protein expression, translocations and fusions, ISH, amplifications, detects gene deletions, NGS, rapidly examines and more broadly detects DNA mutations, copy number variations and gene fusions across the genome, and fragment analysis, that detects changes in RNA or DNA to indicate the absence or presence of genetic marker. Due to this precise detection using biomarkers for the cancer-causing agent, there is an increase in the use of biomarkers for cancer profiling and thereby driving the growth of the cancer/tumor profiling market.

Europe held the second largest share of 27.7% in the global cancer/tumor profiling market in 2016. The growth in the European market for cancer/tumor profiling is mainly led by growing aging population, increasing prevalence of chronic pain, and neurological disorders and R&D infrastructure. By 2023, the European market for cancer/tumor profiling is expected to cross $23.0 billion dollar, growing at a CAGR of 18.5% between 2017-2023. Among all the European countries, Germany held the largest share in the European cancer/tumor profiling industry and is expected to register a CAGR of 19.3% in the forecast period.

Explore Report at:

Some of the other key players operating in the cancer/tumor profiling market include Illumina, Inc., NeoGenomics Inc., Caris Life Sciences, Inc., Oxford Gene Technology, HTG Molecular Diagnostics, Inc., RiboMed Biotechnologies, Inc., QIAGEN N.V. and NanoString Technologies, Inc.

About Vijay K. Advanced   Web Marketing

106 connections, 2 recommendations, 295 honor points.
Joined APSense since, May 17th, 2016, From New York, United States.

Created on Jun 13th 2019 06:05. Viewed 42 times.


No comment, be the first to comment.
Please sign in before you comment.